Switch theme
Sign up to access all valuation multiples
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
1979
53K+
LTM Revenue $17.2B
LTM EBITDA $5.1B
$154B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Boston Scientific has a last 12-month revenue of $17.2B and a last 12-month EBITDA of $5.1B.
In the most recent fiscal year, Boston Scientific achieved revenue of $16.7B and an EBITDA of $3.9B.
Boston Scientific expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Boston Scientific valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $14.2B | $16.7B | XXX | XXX | XXX |
| Gross Profit | $8.7B | $9.9B | XXX | XXX | XXX |
| Gross Margin | 61% | 59% | XXX | XXX | XXX |
| EBITDA | $3.4B | $3.9B | XXX | XXX | XXX |
| EBITDA Margin | 24% | 23% | XXX | XXX | XXX |
| Net Profit | $698M | $1.6B | XXX | XXX | XXX |
| Net Margin | 5% | 10% | XXX | XXX | XXX |
| Net Debt | $8.0B | $8.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 17, 2025, Boston Scientific's stock price is $97.
Boston Scientific has current market cap of $143B, and EV of $154B.
See Boston Scientific trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $154B | $143B | XXX | XXX | XXX | XXX | $2.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 17, 2025, Boston Scientific has market cap of $143B and EV of $154B.
Boston Scientific's trades at 8.9x LTM EV/Revenue multiple, and 30.1x LTM EBITDA.
Analysts estimate Boston Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Boston Scientific and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $154B | XXX | XXX | XXX |
| EV/Revenue | 9.2x | XXX | XXX | XXX |
| EV/EBITDA | 40.0x | XXX | XXX | XXX |
| P/E | 77.3x | XXX | XXX | XXX |
| P/E/Growth | 1.2x | XXX | XXX | XXX |
| EV/FCF | 65.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBoston Scientific's NTM/LTM revenue growth is 13%
Boston Scientific's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Boston Scientific's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Boston Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Boston Scientific and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 36% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 51% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boston Scientific acquired XXX companies to date.
Last acquisition by Boston Scientific was XXXXXXXX, XXXXX XXXXX XXXXXX . Boston Scientific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Boston Scientific founded? | Boston Scientific was founded in 1979. |
| Where is Boston Scientific headquartered? | Boston Scientific is headquartered in United States of America. |
| How many employees does Boston Scientific have? | As of today, Boston Scientific has 53K+ employees. |
| Who is the CEO of Boston Scientific? | Boston Scientific's CEO is Mr. Michael F. Mahoney. |
| Is Boston Scientific publicy listed? | Yes, Boston Scientific is a public company listed on NYS. |
| What is the stock symbol of Boston Scientific? | Boston Scientific trades under BSX ticker. |
| When did Boston Scientific go public? | Boston Scientific went public in 1992. |
| Who are competitors of Boston Scientific? | Similar companies to Boston Scientific include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Boston Scientific? | Boston Scientific's current market cap is $143B |
| What is the current revenue of Boston Scientific? | Boston Scientific's last 12-month revenue is $17.2B. |
| What is the current EBITDA of Boston Scientific? | Boston Scientific's last 12-month EBITDA is $5.1B. |
| What is the current EV/Revenue multiple of Boston Scientific? | Current revenue multiple of Boston Scientific is 8.9x. |
| What is the current EV/EBITDA multiple of Boston Scientific? | Current EBITDA multiple of Boston Scientific is 30.1x. |
| What is the current revenue growth of Boston Scientific? | Boston Scientific revenue growth between 2023 and 2024 was 18%. |
| Is Boston Scientific profitable? | Yes, Boston Scientific is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
